---
title: "CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281017599.md"
description: "CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock News"
datetime: "2026-03-30T04:15:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281017599.md)
  - [en](https://longbridge.com/en/news/281017599.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281017599.md)
generator: "portal-rs"
---

# CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock News

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock News

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [CERO.US](https://longbridge.com/en/quote/CERO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [09:28 ETNew LabCentral Program "The Loop" Offers International Biotech Start-Ups and Partner Organizations Curated Learnings Directly from U.S. Market](https://longbridge.com/en/news/298328140.md)
- [SRX Global buys senior secured debt in CERo Therapeutics Holdings](https://longbridge.com/en/news/297829391.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)
- [CERo Therapeutics Secures Up to $11.67 Million SRX Financing, Consolidates $5.67 Million Debt](https://longbridge.com/en/news/297561416.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**